Key clinical point: An integrated analysis of clinical trial data has refined previously described subgroups of patients with diffuse large B-cell lymphoma (DLBCL).
Major finding: Across the cohort, 38 independent components related to transcriptomic variability were detected, with substantial heterogeneity observed among previously characterized disease subtypes.
Study details: An integrated cohort analysis of 223 patients with de novo CD20+ DLBCL.
Disclosures: The study was funded by the Institut National du Cancer (France). The authors reported financial affiliations with Abbvie, Amgen, BMS, Celgene, Gilead, Pfizer, Roche, and several others.
Dubois S et al. EBioMedicine. 2019 Oct 21. doi: 10.1016/j.ebiom.2019.09.034.